Compare ANIP & EVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANIP | EVT |
|---|---|---|
| Founded | 2001 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 1999 | 2003 |
| Metric | ANIP | EVT |
|---|---|---|
| Price | $78.53 | $25.86 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $110.00 | N/A |
| AVG Volume (30 Days) | ★ 294.9K | 94.1K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 419.23 | N/A |
| EPS | ★ 3.32 | N/A |
| Revenue | ★ $206,547,000.00 | N/A |
| Revenue This Year | $21.01 | N/A |
| Revenue Next Year | $17.59 | N/A |
| P/E Ratio | $23.94 | ★ N/A |
| Revenue Growth | ★ 2.47 | N/A |
| 52 Week Low | $56.71 | $21.87 |
| 52 Week High | $99.50 | $26.65 |
| Indicator | ANIP | EVT |
|---|---|---|
| Relative Strength Index (RSI) | 53.02 | 57.42 |
| Support Level | $78.80 | $25.71 |
| Resistance Level | $83.58 | $26.06 |
| Average True Range (ATR) | 2.41 | 0.37 |
| MACD | -0.04 | 0.05 |
| Stochastic Oscillator | 46.30 | 58.10 |
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.